Danish pharmaceutical giant Novo Nordisk is investing up to $5.2 billion in acquiring Akero Therapeutics, a San Francisco-based biotech developing a treatment for a fatal liver disease. Known for its weight-loss drug Ozempic, Novo Nordisk aims to diversify its portfolio with this new venture.